-
1.发明公开公开(公告)号：US20230390297A1
公开(公告)日：2023-12-07
申请号：US18328011
申请日：2023-06-02
发明人： Ali Shilatifard , Zibo Zhao
IPC分类号： A61K31/519 , A61K31/4375 , A61K31/42 , A61P35/00
CPC分类号： A61K31/519 , A61K31/4375 , A61K31/42 , A61P35/00
摘要： Disclosed herein are methods and compositions for treating a subject comprising the administration of an effective amount of a nucleotide synthesis inhibitor to a subject in need of treatment for a MLL3/4 COMPASS deficient cancer or a MLL3/4 loss of function mutation.
-
公开(公告)号：US20180319795A1
公开(公告)日：2018-11-08
申请号：US16030046
申请日：2018-07-09
IPC分类号： C07D471/04 , C07D233/88
CPC分类号： C07D471/04 , C07D233/88
摘要： Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
-
公开(公告)号：US11071727B2
公开(公告)日：2021-07-27
申请号：US16257581
申请日：2019-01-25
发明人： Ali Shilatifard , Zibo Zhao
IPC分类号： A61K31/4375 , A61P35/02
摘要： Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.
-
公开(公告)号：US11059878B2
公开(公告)日：2021-07-13
申请号：US16355124
申请日：2019-03-15
发明人： Ali Shilatifard , Lu Wang
IPC分类号： C07K14/575 , C07K14/47 , C07K7/06 , C07K16/30 , A61K38/22 , C12Q1/6886 , C12N15/113
摘要： Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
-
公开(公告)号：US20170305901A1
公开(公告)日：2017-10-26
申请号：US15497783
申请日：2017-04-26
IPC分类号： C07D471/04 , C07D233/88
CPC分类号： C07D471/04 , C07D233/88
摘要： Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
-
公开(公告)号：US20210094907A1
公开(公告)日：2021-04-01
申请号：US16981654
申请日：2019-03-21
发明人： Ali Shilatifard , Kaivvei Liang , Edwin R. Smith , Gary E. Schiitz , Rama K. Mishra , Kristen Stoltz
IPC分类号： C07C235/74 , C07C235/78 , C07D241/20 , C07D213/40 , C07D257/06 , C07D271/07 , C07D277/46 , C07D213/75 , C07D239/42 , C07D261/18 , C07D231/14 , C07D239/36 , A61P35/00
摘要： Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
-
公开(公告)号：US20210060001A1
公开(公告)日：2021-03-04
申请号：US16931942
申请日：2020-07-17
发明人： Lu Wang , Ali Shilatifard
IPC分类号： A61K31/473 , A61K31/423 , A61P35/02
摘要： Disclosed are methods for methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex, otherwise referred to herein as the BAP1 complex. In particular, the methods, compounds, and compositions disclosed herein relate to the use of therapeutic agents that inhibit the biological activity of the BAP1 complex for treating cancers such as myeloid neoplasms.
-
公开(公告)号：US10059708B2
公开(公告)日：2018-08-28
申请号：US15497783
申请日：2017-04-26
IPC分类号： C07D471/04 , C07D233/88
CPC分类号： C07D471/04 , C07D233/88
摘要： Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
-
公开(公告)号：US11672794B2
公开(公告)日：2023-06-13
申请号：US16931942
申请日：2020-07-17
发明人： Lu Wang , Ali Shilatifard
IPC分类号： A61K31/473 , A61P35/02 , A61K31/423
CPC分类号： A61K31/473 , A61K31/423 , A61P35/02
摘要： Disclosed are methods for methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex, otherwise referred to herein as the BAP1 complex. In particular, the methods, compounds, and compositions disclosed herein relate to the use of therapeutic agents that inhibit the biological activity of the BAP1 complex for treating cancers such as myeloid neoplasms.
-
公开(公告)号：US11453640B2
公开(公告)日：2022-09-27
申请号：US16981654
申请日：2019-03-21
发明人： Ali Shilatifard , Kaiwei Liang , Edwin R. Smith , Gary E. Schiltz , Rama K. Mishra , Kristen Stoltz
IPC分类号： C07C235/74 , A61P35/00 , C07C235/78 , C07D213/40 , C07D213/75 , C07D231/14 , C07D239/36 , C07D239/42 , C07D241/20 , C07D257/06 , C07D261/18 , C07D271/07 , C07D277/46
摘要： Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.016 秒)
